(0.10%) 5 522.25 points
(0.14%) 39 898 points
(0.20%) 19 791 points
(-0.06%) $81.58
(0.57%) $2.83
(-0.23%) $2 339.00
(0.15%) $29.57
(0.45%) $1 006.30
(0.05%) $0.932
(-0.04%) $10.53
(0.02%) $0.788
(-0.85%) $87.25
2.37% $ 2.16
Live Chart Being Loaded With Signals
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers...
Stats | |
---|---|
Dzisiejszy wolumen | 2.38M |
Średni wolumen | 1.60M |
Kapitalizacja rynkowa | 561.27M |
EPS | $-0.230 ( Q1 | 2024-05-08 ) |
Następna data zysków | ( $-0.170 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.57 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00600 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Varney Michael David | Buy | 60 000 | Stock Option (right to buy) |
2024-06-20 | Start Valerie Denise Harding | Buy | 60 000 | Stock Option (right to buy) |
2024-06-20 | Liu Jean I | Buy | 60 000 | Stock Option (right to buy) |
2024-06-20 | Garner Ebun | Buy | 160 082 | Stock Option (right to buy) |
2024-06-20 | Morris Shannon | Buy | 137 142 | Stock Option (right to buy) |
INSIDER POWER |
---|
94.45 |
Last 97 transactions |
Buy: 51 526 214 | Sell: 10 940 033 |
Wolumen Korelacja
Erasca, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Erasca, Inc. Korelacja - Waluta/Towar
Erasca, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.73M (0.00 %) |
EPS: | $-0.830 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.73M (0.00 %) |
EPS: | $-0.830 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-2.64M (0.00 %) |
EPS: | $-1.950 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.790 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Erasca, Inc.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company\'s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej